亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Selonsertib in adults with pulmonary arterial hypertension (ARROW): a randomised, double-blind, placebo-controlled, phase 2 trial

医学 安慰剂 耐受性 内科学 西地那非 安慰剂对照研究 双盲 临床试验 肺动脉高压 临床终点 不利影响 病理 替代医学
作者
Stephan Rosenkranz,Jeremy Feldman,Vallerie V. McLaughlin,Franz Rischard,Tobias Lange,R. James White,Andrew J. Peacock,Felix Gerhardt,Ramin Ebrahimi,Gabriel Brooks,Carol Satler,Robert P. Frantz
出处
期刊:The Lancet Respiratory Medicine [Elsevier BV]
卷期号:10 (1): 35-46 被引量:23
标识
DOI:10.1016/s2213-2600(21)00032-1
摘要

Background Data obtained in human lung tissue and preclinical models suggest that oxidative stress and increased apoptosis signal-regulating kinase 1 (ASK1) activity might have a prominent role in the pathobiology of pulmonary arterial hypertension (PAH). The purpose of this study was to determine the efficacy, safety, and tolerability of the ASK1 inhibitor selonsertib compared with placebo in patients with PAH. Methods We did a randomised, double-blind, placebo-controlled, phase 2 trial at 46 centres located in Canada, France, Germany, Italy, the Netherlands, Spain, the UK, and the USA. Participants were aged 18–75 years and had an established diagnosis of idiopathic or hereditary PAH, or PAH associated with connective tissue disease, drugs or toxins, human immunodeficiency virus, or repaired congenital heart defects. Patients were stratified by PAH aetiology and background therapy, and randomly assigned (1:1:1:1) using an interactive voice-response or web-response system to placebo or selonsertib 2 mg, 6 mg, or 18 mg administered orally once daily. Both placebo and selonsertib were in tablet form. The primary efficacy endpoint was change in pulmonary vascular resistance, measured by right heart catheterisation, from baseline to week 24 in the full analysis set. Pair-wise comparisons between each of the selonsertib groups and the placebo group were made with a stratified Wilcoxon (van Elteren) rank sum test for participants without major protocol deviations who received at least one dose of study drug. This trial is registered with ClinicalTrials.gov, NCT02234141. Findings Between Dec 3, 2014, and Nov 13, 2015, 151 patients were enrolled and randomly assigned. Of 150 participants who received selonsertib or placebo, 134 (89%) completed 24 weeks of the randomly assigned treatment; all were on background PAH therapy (138 [92%] on combination therapy). 90 (60%) patients were in functional class II and 60 (40%) in functional class III. Mean baseline pulmonary vascular resistance was 772 (SD 334) dyn·s/cm5. Change in pulmonary vascular resistance was 6·0 dyn·s/cm5 (SD 28·0; n=31) for placebo, and 35·0 (35·4) dyn·s/cm5 (n=35; p=0·21 vs placebo) for 2 mg selonsertib, −28·0 (30·2) dyn·s/cm5 (n=34; p=0·27 vs placebo) for 6 mg selonsertib, and −21·0 (37·9) dyn·s/cm5 (n=36; p=0·60 vs placebo) for 18 mg selonsertib. The most frequent adverse events were headache (17 [15%]), abnormal dreams (eight [7%]), nausea (seven [6%]), and diarrhoea (seven [6%]) in the selonsertib groups, and headache (six [16%]), nausea (five [14%]), and diarrhoea (two [5%]) in the placebo group. Serious adverse events occurred in 23 (20%) of 113 selonsertib-treated patients and seven (19%) of 37 patients who received placebo. Interpretation Selonsertib once daily for 24 weeks did not lead to a significant reduction in pulmonary vascular resistance or to clinical improvement in patients with PAH, but appeared to be safe and well tolerated. Although these data do not support the clinical use of selonsertib in PAH, further study of the potential of targeting the ASK1–p38 pathway in PAH is warranted. Funding Gilead Sciences.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
5秒前
11秒前
38秒前
42秒前
33应助可靠的寒风采纳,获得20
43秒前
量子星尘发布了新的文献求助10
59秒前
1分钟前
JamesPei应助背后梦安采纳,获得10
1分钟前
1分钟前
祖之微笑发布了新的文献求助10
1分钟前
祖之微笑完成签到,获得积分10
1分钟前
1分钟前
Magali发布了新的文献求助10
1分钟前
2分钟前
2分钟前
2分钟前
shinian完成签到,获得积分10
2分钟前
shinian发布了新的文献求助10
2分钟前
2分钟前
2分钟前
哈尔滨发布了新的文献求助10
2分钟前
背后梦安发布了新的文献求助10
2分钟前
量子星尘发布了新的文献求助10
2分钟前
2分钟前
zhen完成签到,获得积分10
3分钟前
哈尔滨完成签到,获得积分20
3分钟前
3分钟前
米奇妙妙屋完成签到,获得积分10
4分钟前
tylscxf完成签到,获得积分10
4分钟前
YifanWang完成签到,获得积分0
4分钟前
量子星尘发布了新的文献求助30
4分钟前
4分钟前
启震发布了新的文献求助10
4分钟前
4分钟前
4分钟前
5分钟前
5分钟前
www完成签到,获得积分20
5分钟前
5分钟前
风车术完成签到,获得积分20
5分钟前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3976649
求助须知:如何正确求助?哪些是违规求助? 3520756
关于积分的说明 11204743
捐赠科研通 3257502
什么是DOI,文献DOI怎么找? 1798733
邀请新用户注册赠送积分活动 877897
科研通“疑难数据库(出版商)”最低求助积分说明 806629